

Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo- β -lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections

Bin Liu,^{*,†} Robert E. Lee Trout,[†] Guo-Hua Chu,[†] Daniel McGarry,[†] Randy W. Jackson,[†] Jodie C. Hamrick,[†] Denis M. Daigle,[†] Susan M. Cusick,[†] Cecilia Pozzi,[‡] Filomena De Luca,[§] Manuela Benvenuti,[‡] Stefano Mangani,[‡] Jean-Denis Docquier,[§] William J. Weiss,^{||} Daniel C. Pevear,[†] Luigi Xerri,[†] and Christopher J. Burns^{*,†}

[†]Venatorx Pharmaceuticals, Inc., 30 Spring Mill Drive, Malvern, Pennsylvania 19355, United States


[‡]Department of Biotechnology, Chemistry and Pharmacy, University of Siena, I-53100 Siena, Italy

[§]Department of Medical Biotechnology, University of Siena, I-53100 Siena, Italy

^{||}UNT System College of Pharmacy, University of North Texas Health Science Center, 3500 Camp Bowie Boulevard, Fort Worth, Texas 76107-2699, United States

Supporting Information

ABSTRACT: A major resistance mechanism in Gram-negative bacteria is the production of β -lactamase enzymes. Originally recognized for their ability to hydrolyze penicillins, emergent β -lactamases can now confer resistance to other β -lactam drugs, including both cephalosporins and carbapenems. The emergence and global spread of β -lactamase-producing multi-drug-resistant “superbugs” has caused increased alarm within the medical community due to the high mortality rate associated with these difficult-to-treat bacterial infections. To address this unmet medical need, we initiated an iterative program combining medicinal chemistry, structural biology, biochemical testing, and microbiological profiling to identify broad-spectrum inhibitors of both serine- and metallo- β -lactamase enzymes. Lead optimization, beginning with narrower-spectrum, weakly active compounds, provided **20** (VNRX-5133, taniborbactam), a boronic-acid-containing pan-spectrum β -lactamase inhibitor. In vitro and in vivo studies demonstrated that **20** restored the activity of β -lactam antibiotics against carbapenem-resistant *Pseudomonas aeruginosa* and carbapenem-resistant Enterobacteriaceae. Taniborbactam is the first pan-spectrum β -lactamase inhibitor to enter clinical development.



20 (VNRX-5133, Taniborbactam)

INTRODUCTION

β -Lactam antibiotics (BLs), including penicillins, cephalosporins, monobactams, and carbapenems, represent the most important group of antibiotics, accounting for >50% of all antibiotic prescriptions.¹ BLs inhibit bacterial cell-wall biosynthesis by binding to penicillin-binding proteins (PBPs), thus preventing peptidoglycan cross-linking and ultimately causing bacterial cell death. Although BLs are safe and demonstrate high efficacy in the clinical setting, the overuse of BLs has resulted in the emergence and spread of BL-resistant bacteria, which has progressively eroded their clinical utility. Mechanisms of resistance to BLs include the overproduction of efflux pumps, the modification or down-regulation of outer-membrane porins (in Gram-negative bacteria), the modification of PBPs (especially in Gram-positive bacteria), and the evolution of β -lactamase enzymes that catalytically inactivate BLs by hydrolyzing the β -lactam ring. Over eight decades of BL use, bacteria have evolved an extraordinary number of β -lactamase variants (>2000 reported to date) exhibiting

significant structural and functional heterogeneity resulting from the introduction of different BLs approved for medical use.² On the basis of amino acid sequence homology, β -lactamases are divided into four classes (Ambler classification): A, B, C, and D.³ Classes A, C, and D are serine β -lactamases (SBLs), including the clinically relevant TEM-, SHV-, CTX-M-, and KPC-type variants (class A), the AmpC- and the plasmid-encoded CMY-type cephalosporinases (class C), and the OXA-type enzymes (oxacillinases, class D). Class B β -lactamases are zinc-dependent metallo- β -lactamases (MBLs) characterized by an exceedingly broad substrate profile and strong carbapenemase activity. MBLs are classified into three subclasses (B1, B2, and B3) based on the primary amino acid sequence.⁴ Subclass B1 includes clinically important NDM-, IMP-, and VIM-type variants. KPC-, OXA-, NDM-, VIM-, and IMP-type β -lactamases are mostly encoded by plasmids in


Received: September 12, 2019

Published: November 25, 2019



clinical isolates of Enterobacteriaceae, *Pseudomonas* spp., and *Acinetobacter* spp., thus giving rise to the emergence and spread of multi-drug-resistant (MDR) Gram-negative opportunistic pathogens, which threaten the ability to efficiently treat hospital-acquired infections.⁵ Global antibiotic resistance has reached critical levels, with major bacterial pathogens (including Gram-negative organisms such as *Escherichia coli*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, and *Pseudomonas aeruginosa*) quickly evolving toward pan-drug-resistant phenotypes. There is an urgent medical need for strategies that address both serine- and metallo-based β -lactamase-mediated bacterial resistance.

One successful strategy for overcoming β -lactamase-mediated resistance is to coadminister the BL with an appropriate β -lactamase inhibitor (BLI). Under these combinations, the BLI forms a covalent adduct with the active SBL enzyme, thereby preventing it from hydrolyzing the BL antibiotic. Three therapeutically important BLIs, that is, clavulanic acid, tazobactam (TZB), and sulbactam (Figure 1), are effective against certain class A SBLs but are mostly

β -Lactam-based BLI



DBO-based BLI



Boronic acid-based BLI




Figure 1. Structures of the approved BLIs.

ineffective against class C cephalosporinases, carbapenem-hydrolyzing serine enzymes (KPC- and OXA-type), and class B MBLs (including NDM- and VIM-type MBLs). In addition, these first-generation BLIs are themselves β -lactams that have driven the rapid evolution of resistance to these structurally similar compounds (e.g., inhibitor-resistant variants). A next wave of BLI discovery led to the approval of the diazabicyclooctane (DBO) avibactam (AVI) (NXL-104) in 2015 and relebactam in 2019 (Figure 1). The DBOs display a broad spectrum of β -lactamase inhibition, which includes KPC-type and some of the class D OXA-type enzymes.⁶ Studies have shown that AVI is a covalent and slowly reversible inhibitor.⁷ Another reversible BLI vaborbactam (VAB) (RPX7009) was the first approved boron-based BLI that also efficiently inhibits KPC-type carbapenemases.⁸ However, the DBOs and VAB lack activity against MBLs. There is a clear, unmet medical need for the development of broad-spectrum BLIs that would exhibit inhibitory activity against class A, B, C, and D enzymes, especially considering that β -lactamases belonging to multiple classes are now commonly produced by MDR Gram-negative pathogens.

Boronic acids and esters are electrophilic moieties that covalently bind the active-site serine residue of certain enzymes, including SBLs. Thus boronic acids or esters have been successfully developed as enzyme inhibitors.⁹ The covalent tetrahedral adduct formed between the boron atom of the inhibitor and the catalytic serine residue of the β -

lactamase mimics either the acylation or deacylation step of the enzyme-mediated hydrolysis. Although the boron covalently binds to the enzyme, the inhibitors are reversible in nature.¹⁰ Because boron-based BLIs are not β -lactams, they have the added benefit of not being inactivated by β -lactam-recognizing enzymes. The preliminary discovery of boron-based BLIs emanated from academic laboratories;^{10–15} however, over the past decade, the pharmaceutical industry has shown increased interest in this field. The bicyclic boronates were first discovered and disclosed as pan-spectrum BLIs (i.e., able to inhibit both SBLs and MBLs) by Burns et al. at Protez Pharmaceuticals (a subsidiary of Novartis) in 2010.¹⁶ The class of bicyclic boronate BLIs was then further developed at Venatorx Pharmaceuticals.^{17,18} Subsequently, additional structural and mechanistic studies of bicyclic boronate BLIs appeared in the literature.^{19–22} In parallel, Rempex Pharmaceuticals has discovered and developed the monocyclic boron-based SBL inhibitor, RPX7009 (VAB), which has been approved for use in combination with meropenem.⁸ Herein we describe the iterative program including medicinal chemistry, structural biology, biochemical testing, and microbiological profiling that led to the discovery of VNRX-5133 (taniborbactam), a highly potent pan-spectrum BLI that inhibits all four Ambler classes of β -lactamase enzymes with excellent Gram-negative outer membrane penetration.^{17,23} The combination of VNRX-5133 with the fourth-generation cephalosporin, cefepime, is currently in phase 3 clinical studies.

RESULTS AND DISCUSSION

Design of BLIs for Both Serine- and Metallo- β -lactamases (“Pan-Spectrum BLIs”). Ness et al. described the design of boronic acids **1** as inhibitors of TEM-1, a narrow-spectrum SBL (Figure 2).²⁴ Using structure-based design, the




Figure 2. Chemical structures and proposed equilibria of known cyclic boronates **1**–**3**.

authors reasoned that the introduction of a hydroxyl group onto the aromatic ring of **2** might facilitate intramolecular cyclization (i.e., **1b**) or provide an additional hydrogen-bonding interaction with the enzyme. Indeed, compound **1** showed a significant increase in affinity to the TEM-1 enzyme compared with **2**. However, X-ray crystallography revealed that **1** was binding in the acyclic binding mode (i.e., **1a**). Burns et al. expanded this concept by introducing a further substituted acetamide group.¹⁶ Extensive structure–activity relationship (SAR) studies and microbiological profiling identified a series of compounds exemplified as **3** with potent activity against a broad panel of SBLs and weak activity against certain class B metallo-enzymes. This study also suggested the cyclic boronate **3b** as a possible β -lactamase binding mode.¹⁶ In our hands, the enzymatic activity of **1** and **3** against both class A KPC-type and class C β -lactamases appeared suboptimal, as small

structural changes resulted in vastly different IC_{50} values. In addition, **1** and **3** only inhibited the MBL VIM-2 at micromolar levels. On the basis of the published X-ray cocrystal structures of **1** with TEM-1 β -lactamase,²⁴ we understood that the boron atoms of **1** and **3** were interacting covalently with the active-site serine residue. For MBL binding, we hypothesized that the carboxylic acid group, cyclic boronate oxygen, and hydroxyl groups might be interacting with the active-site zinc atoms. Thus we recognized that the cyclic boronate scaffold might serve for the development of a pan-spectrum BLI.

Our design strategy was to append the cyclic boronate scaffold with a hydrophobic group to enhance van der Waals interactions between the ligand and hydrophobic residues within the β -lactamase active site (Figure 3). Notably, both SBL and MBL enzymes commonly contain hydrophobic residues in the loops defining this portion of the active site pocket.²⁵





Figure 3. Strategy for designing a cyclic boronate-based pan-BLI showing putative active-site serine- or zinc-binding interactions.

Because of the vast diversity of clinically relevant β -lactamase-producing bacteria, broad-spectrum BLs and BLIs must be able to cross the outer membrane (OM) of multiple Gram-negative pathogens to be classified as an effective therapeutic agent. The entry of nutrients and xenobiotics through the OM is highly controlled and often facilitated by the OM porins—a family of transmembrane hydrophilic channels that allow for the passive transport of molecules into the periplasm.²⁶ O'Shea et al. have observed that high-molecular-weight BLs with $\log P < 1$ and polar surface area (PSA) $> 150 \text{ \AA}^2$ have preferred access into Gram-negative bacteria.²⁷ Thus, to bias entry into Gram-negative bacteria, polar group(s) would be ideally included in the amide group substituent of the designed BLIs (Figure 3).

Synthesis of the Cyclic Boronate-based BLIs. The cyclic boronate-based BLIs were prepared using modifications of previously reported procedures (Scheme 1).¹⁶ Compound **4** was synthesized in two steps from commercially available 3-borono-2-methoxybenzoic acid by a reaction with isobutylene, followed by the esterification of the boronic acid with (+)-pinanediol. Following Matteson's protocol,²⁸ the aryl boronate (**4**) was reacted with chloromethyl lithium at $-100 \text{ }^\circ\text{C}$ to provide **5** in excellent yield. A second homologation reaction with the anion derived from dichloromethane ($-100 \text{ }^\circ\text{C}$) selectively provided the (*S*)- α -chloro-boronate (**6**). Stereospecific displacement of the chlorine atom of **6** with lithium bis(trimethylsilyl)amide at $-20 \text{ }^\circ\text{C}$ afforded the intermediate α -silylaminoboronate (**7**), which was coupled in

Scheme 1. Generalized Synthesis of Cyclic Boronate-based BLIs



situ (HATU, NMM) to the requisite carboxylic acid. The resultant amides (**8**) were deprotected and cyclized by treatment with BCl_3 (1 M in DCM) at $-78 \text{ }^\circ\text{C}$ to afford the crude boronates (**9**), which were purified by reverse-phase high-performance liquid chromatography (HPLC) then lyophilized to dryness.

The carboxylic acids (RCO_2H) used for SAR studies were either commercially available or synthesized from readily available starting materials. A representative synthesis of carboxylic acid side chain **14** is provided in Scheme 2. In this case, the alkylation of acid **10** with benzyl bromide gave ester **11**. The removal of the Boc protective group afforded the amine HCl salt (**12**), which was converted to intermediate **13** via reductive amination. The protection of the secondary amine and the removal of the benzyl group provided **14** in a ca. 30% yield over five steps.

Structure–Activity Relationship. The cyclic boronates were evaluated for both inhibition of selected β -lactamase enzymes and rescue of meropenem activity in selected meropenem-resistant bacterial strains. Our primary in-house biochemical screening panel was composed of four β -lactamases belonging to each of the four unique enzyme classes. Cellular assays were performed using meropenem-resistant *Klebsiella pneumoniae* and *Pseudomonas aeruginosa* isolates and the minimum inhibitory concentrations (MICs) of the BL/BLI combinations were determined using a fixed concentration of meropenem ($4 \text{ } \mu\text{g/mL}$). Importantly, three *K. pneumoniae* strains had acquired meropenem resistance, in part, due to the production of certain β -lactamase enzymes, that is, KPC-2, OXA-48, and VIM-4, whereas the non-fermenting *P. aeruginosa* strain predominantly produced VIM-2. The MIC values of meropenem alone against these strains are $\geq 32 \text{ } \mu\text{g/mL}$.

Our initial efforts focused on the replacement of the aryl group of **3** with a cyclohexyl moiety. We reasoned that a cyclohexyl group might offer a different trajectory to possibly place the attached polar group in a productive interaction with the amino acids of β -lactamases and improve the physicochemical properties owing to the increased sp^3 character of the inhibitor.²⁹ When evaluated against our primary panel of β -lactamase enzymes and bacterial isolates, **3** displayed potent inhibition of the class A KPC-2 carbapenemase and AmpC-type enzymes but only modest inhibition of the class D OXA-48 carbapenemase. The excellent MIC of **3** plus meropenem

Scheme 2. Synthesis of Carboxylic Acid 14





Table 1. Biochemical and Microbiological Activity of BLIs 3 and 15–17



entry	clogP	tPSA	biochemical assay, IC ₅₀ (μM) ^b				microbiological assay, MIC (μg/mL) ^a			
							<i>K. pneumoniae</i>		<i>P. aeruginosa</i>	
			KPC-2 (class A)	AmpC (class C)	OXA-48 (class D)	VIM-2 (class B)	KPC-2	OXA-48	VIM-4	VIM-2
3	-1.67	122	0.04	0.012	1.8	0.27	0.5	1	4	8
15	-1.04	122	0.10	0.025	1.8	1.6	1	2	8	4
16	-1.66	122	0.12	0.005	18.0	1.67	2	16	32	32
17	-1.66	122	0.03	0.03	2.24	0.15	2	2	2	2

^aReported as the BLI concentration able to restore meropenem (fixed at 4 μg/mL) antibacterial activity. ^bResults are expressed as the average from duplicates unless otherwise indicated.


(fixed at 4 μg/mL) against the KPC-2-producing *K. pneumoniae* strain (MIC = 0.5 μg/mL) suggested a reasonable accumulation of the drug in this Gram-negative pathogen (Table 1). However, despite the modest inhibition of the VIM-2 MBL, 3 was less effective at rescuing meropenem activity in VIM-producing strains. The cyclohexyl analogue (15) showed comparable inhibition of KPC-2, AmpC, and OXA-48 to 3 but possessed reduced activity against VIM-2. The truncation of the terminal alkyl amine afforded the 1,4-*cis*- and 1,4-*trans*-cyclohexylamines 16 and 17, respectively. Relative to 15, analogue 16 had reduced inhibitory activity against OXA-48 and comparable activity against VIM-2. The higher MIC values of 16 relative to 15 for the VIM-producing isolates, however, suggested that this truncated 1,4-*cis*-cyclohexylamine was less able to accumulate in the periplasm. Gratifyingly, the isomeric 1,4-*trans*-17 demonstrated significant inhibitory activity against all four classes of β-lactamases, with a striking low-nanomolar inhibition of the VIM-2 MBL and a potent rescue of meropenem (4 μg/mL) observed in the presence of 2 μg/mL of BLI in the meropenem-resistant isolates.

In an effort to modify the molecular properties of the inhibitors (i.e., MW, clogP, PSA, and net charge at physiological pH), we substituted the terminal amine of 17 with a variety of polar and nonpolar groups and observed how these factors affected the enzyme inhibition and Gram-negative

bacteria OM penetration (Table 2). Acetic acid analogue 18 and ethanolamine analogue 19 only poorly inhibited the VIM-2 MBL. However, when an additional amine group was added, as in 20, we observed a dramatic improvement in the enzyme inhibition against both OXA-48 and VIM-2 β-lactamases. Importantly, 20 demonstrated excellent potentiation of meropenem activity in the whole-cell assay, which suggested excellent penetration across the Gram-negative OM. Comparing 20 with 19 and 18, we observed that replacing the neutral hydroxyl group or negatively charged carboxylate with a primary amine could dramatically increase the inhibitory activity toward VIM-2 and OXA-48 and, most importantly, improve the BLI permeability toward the Gram-negative OM. Conversely, constrained diamine 21 had reduced activity in the biochemical and cell-based assays. Notably, relative to 20, both the 1,4-*cis*-22 and aryl analogue 23 displayed reduced biochemical activity against VIM-2.

Additional analogues were prepared to vary the basicity, the distance from the cyclohexylamine moiety, the steric environment, and the geometry of the attached distal substituent. The replacement of the distal amino group with guanidine (24) or methylsulfonamide (25) did not significantly alter in vitro enzyme inhibition, albeit with modest loss of activity on OXA-48 and VIM-2, respectively (Table 3). Additionally, 25 exhibited a significant loss in whole-cell activity possibly due


Table 2. Biochemical and Microbiological Activity of BLIs 18–23



entry	clogP	tPSA	biochemical assay, IC ₅₀ (μM) ^b				microbiological assay, MIC (μg/mL) ^a			
			KPC-2 (class A)	AmpC (class C)	OXA-48 (class D)	VIM-2 (class B)	<i>K. pneumoniae</i>			<i>P. aeruginosa</i>
							KPC-2	OXA-48	VIM-4	VIM-2
18	-1.85	145	0.019	0.006	3.14	2.4	4	8	32	16
19	-1.99	128	0.017	0.01	7.55	1.4	2	2	0.5	4
20	-2.39	134	0.03	0.032	0.42	0.02	0.5	2	0.5	0.06
21	-1.32	111	0.02	0.003	1.52	1.5	4	16	32	16
22	-2.39	134	0.03	0.035	0.67	0.13	8	8	4	0.5
23	-1.81	134	0.022	0.005	0.288	0.491	1	1	8	0.5

^aReported as the BLI concentration able to restore meropenem (fixed at 4 μg/mL) antibacterial activity. ^bResults are expressed as the average from duplicates unless otherwise indicated.

Table 3. Biochemical and Microbiological Activity of BLIs 24–29



entry	clogP	tPSA	biochemical assay, IC ₅₀ (μM) ^b				microbiological assay, MIC (μg/mL) ^a			
			KPC-2 (class A)	AmpC (class C)	OXA-48 (class D)	VIM-2 (class B)	<i>K. pneumoniae</i>			<i>P. aeruginosa</i>
							KPC-2	OXA-48	VIM-4	VIM-2
24	-2.53	170	0.027	0.006	1.59	0.086	1	2	0.06	0.5
25	-1.97	154	0.017	0.006	0.499	0.11	4	8	8	16
26	-1.66	132	0.036	0.014	0.454	0.477	1	8	8	1
27	-2.60	151	0.034	0.006	0.355	0.594	2	8	8	8
28	-1.61	119	0.012	0.011	0.579	0.002	0.5	2	0.5	N.D. ^c
29	-1.97	134	0.07	0.005	0.664	0.082	0.5	8	4	0.25

^aReported as the BLI concentration able to restore meropenem (fixed at 4 μg/mL) antibacterial activity. ^bResults are expressed as the average from duplicates unless otherwise indicated. ^cNot determined.

to poor penetration. Imidazole replacement (**26**) or the introduction of a carbonyl group (**27**) were detrimental to pan-β-lactamase activity compared with **20**. The introduction of a methyl group to the distal nitrogen atom (**28**) resulted in improved inhibition with VIM-2 in the biochemical assays and was well tolerated in the cell-based assay. Furthermore, increasing the distance between the two nitrogen atoms (**29**) was also well tolerated in the biochemical assays.

Taken together, these data suggest that cyclic boronates have the potential to potently inhibit both SBLs and MBLs with a variety of substituents occupying the β-lactamase active

site(s). Because of the permeability barrier of Gram-negative bacteria, however, lead optimization focused on identifying the desired amide-based side chain that would partially mediate OM permeability. We noticed that the preferred analogues to achieve better Gram-negative OM penetration possessed a clogP value between -1 and -2.5 and a tPSA between 110 and 170 Å². The addition of a second amino or guanidino group, which is protonated at physiological pH, appeared to be beneficial for the Gram-negative OM permeability. In addition, the steric environment surrounding the distal amine was critical, with a primary amine or a secondary amine bearing a

Table 4. Inhibitory Activity of **20** and Known BLIs Measured with Clinically Relevant β -Lactamases of Classes A to D

entry	IC_{50} (μM) ^{a,b}										
	class A			class C			class D		class B		
	SHV-5	CTX-M-15	KPC-2	CMY-2	p99 AmpC	OXA-1	OXA-48	NDM-1	VIM-2	IMP-1	
20	0.0004	0.01	0.03	0.007	0.03	0.16	0.42 (0.54) ²²	0.19	0.026	39.8 (2.51) ²²	
avibactam	0.013	0.003	0.06	0.007	0.016	0.04	0.55	>100	>100	>100	
vaborbactam	0.44	0.42	0.1	0.22	0.09	7.9	38.8 (25) ³¹	>100 (631) ³¹	>100 (316) ³¹	>100 (126) ³¹	
clavulanic acid	0.012	0.04	1.8	>100	>100	0.12	30	>100	>100	>100	
tazobactam	0.015	0.001	1.7	0.41	0.73	0.43	0.55	>100	>100	>100	

^aResults are expressed as the average from duplicates unless otherwise indicated. ^b IC_{50} values reported in the literature are shown in parentheses.




Figure 4. Co-crystal structures of CTX-M-15/**20** (A, PDB ID: 6SP6) and VIM-2/**20** (B, PDB ID: 6SP7).

small alkyl group being preferred for increased permeability. Richter et al. recently showed that a primary amino group (together with high rigidity and low globularity) could predict compound accumulation within Gram-negative bacteria.³⁰ We propose that in addition to the polarity of the compound, the net charge of the molecule may have an important role. The inclusion of an amine moiety can alter the net charge of a compound at physiological pH and might be a contributing factor for improved Gram-negative OM penetration. Following this preliminary investigation, compound **20** (VNRX-5133) was selected for further evaluation as a potential development candidate owing to its potency against the four classes of β -lactamases as well as its broad range of cellular activity in combination with meropenem.

Compound **20 Inhibited both Serine- and Metallo- β -lactamases.** Cyclic boronate **20** and four known BLIs were tested against a panel consisting of the four classes of β -lactamase enzymes (A–D). As described in Table 4, **20** exhibited a broad spectrum of activity, inhibiting all of the class A, C, and D SBLs tested as well as two of the class B MBLs. In contrast, the two β -lactam-derived BLIs, clavulanic acid and TZB, showed reduced activity on KPC-2, CMY-2, and AmpC. The recently approved boronic-acid-based BLI, VAB, showed good activity against KPC-2 but was only weakly active against the SHV-5 and CTX-M-15 extended-spectrum β -lactamases (ESBLs) and the OXA-type variants. Importantly, unlike AVI, VAB, clavulanic acid, and TZB, **20** displayed significant inhibition of the clinically relevant NDM-1 and VIM-2 MBLs. However, **20** was only weakly active against IMP-1, another clinically relevant subclass B1 MBL. A recent study also reported a similar spectrum of activity for VNRX-5133

against β -lactamases.²² In addition, the authors observed that VNRX-5133 was weakly active against the subclass B2 MBL CphA ($IC_{50} \approx 2.51 \mu M$) and did not inhibit subclass B3 MBL Ll.²²

Crystallography. To explore the structural basis for the pan- β -lactamase inhibition of **20**, we determined the structures of the class A ESBL CTX-M-15 and the VIM-2 MBL in complex with **20** at 1.1 and 1.8 Å resolution.³² Notably, several cocrystal structures of cyclic boronates including **20** in complex with the four classes of β -lactamases including CTX-M-15,²⁰ AmpC,³³ OXA-10,^{19,22} VIM-2,¹⁹ BcII,¹⁹ and NDM-1²² have been reported. Together, these crystallographic studies reveal the structural basis for the dual inhibition of both SBLs and MBLs. As shown in Figure 4A, the structure of **20**/CTX-M-15 shows that the boron-based BLI interacts with the β -lactamase in the closed or cyclic form. The catalytic Ser70 of the enzyme is covalently bound to the boron atom of **20**. One hydroxyl group on the boron atom is located in the oxyanion hole, thus mimicking the acylation tetrahedral intermediate. The amide moiety of the inhibitor forms important interactions with the enzyme, donating a hydrogen bond to the Ser237 backbone carbonyl and accepting hydrogen bonds from the side chains of both Asn132 and Asn104, residues that are largely conserved in class A and class C enzymes. The carboxylate of **20** forms hydrogen bonds with the Thr235 (which belong to the K²³⁴TG conserved motif) and Ser237 side chains. The cyclohexyl moiety of **20** occupies the same space where the aryl group of several penicillins and cephalosporins resides. The ethyl diamine appendage is directed toward a crystallographic water molecule, with no apparent direct interaction with the enzyme. Overall, the

Table 5. MICs against Selected Gram-Negative Pathogens for Piperacillin (PIP) and Piperacillin Plus 20

species	strain ID	β -lactamase content	PIP MIC ($\mu\text{g/mL}$)	MIC with piperacillin fixed at 16 $\mu\text{g/mL}$ ($\mu\text{g/mL}$)						
				20	17	1	3	VAB	TZB	AVI
<i>K. pneumoniae</i>	ATCC BAA 1705	KPC-2	>128	4	4	2	2	>16	>16	4
<i>K. pneumoniae</i>	CDC-0040	VIM-27, CTX-M-15, SHV-11, OXA-1	>128	16	>16	>16	>16	>16	>16	>16
<i>E. coli</i>	CDC-0055	NDM-1, CMY-6, OXA-1	>128	16	>16	>16	16	>16	>16	16
<i>K. pneumoniae</i>	CDC-0066	OXA-232, OXA-9, TEM-1A, CTX-M-15, OXA-1	>128	>16	>16	>16	>16	>16	>16	8
<i>P. aeruginosa</i>	CDC-0356	KPC-2, PDC-42	>128	1	4	2	2	>16	>16	1
<i>K. pneumoniae</i>	CDC-0361	KPC-2, SHV-12, TEM-1	>128	1	2	2	0.5	>16	>16	2
<i>E. coli</i>	CDC-0452	NDM	>128	2	>16	>16	8	>16	>16	8
<i>P. aeruginosa</i>	CDC-0457	VIM	64	16	>16	>16	>16	>16	>16	>16

Table 6. MICs against Selected Gram-Negative Pathogens for Cefepime (FEP) and Cefepime Plus 20

species	strain ID	β -lactamase content	FEP MIC ($\mu\text{g/mL}$)	MIC with cefepime fixed at 8 $\mu\text{g/mL}$ ($\mu\text{g/mL}$)						
				20	17	1	3	VAB	TZB	AVI
<i>K. pneumoniae</i>	ATCC BAA 1705	KPC-2	16	0.06	0.125	0.0079	0.06	0.25	>16	0.06
<i>K. pneumoniae</i>	CDC-0040	VIM-27, CTX-M-15, SHV-11, OXA-1	>128	4	>16	>16	>16	>16	>16	>16
<i>E. coli</i>	CDC-0055	NDM-1, CMY-6, OXA-1	128	2	>16	>16	4	>16	>16	16
<i>K. pneumoniae</i>	CDC-0066	OXA-232, OXA-9, TEM-1A, CTX-M-15, OXA-1	>128	2	4	1	4	>16	>16	1
<i>P. aeruginosa</i>	CDC-0356	KPC-2, PDC-42	>128	1	4	2	2	>16	>16	1
<i>K. pneumoniae</i>	CDC-0361	KPC-2, SHV-12, TEM-1	32	0.015	0.015	0.0079	0.0079	>16	16	0.0079
<i>E. coli</i>	CDC-0452	NDM	64	0.125	4	8	2	>16	>16	8
<i>P. aeruginosa</i>	CDC-0457	VIM	16	0.125	2	>16	8	>16	>16	>16

Table 7. MICs against Selected Gram-Negative Pathogens for Meropenem (MEM) and Meropenem Plus 20

species	strain ID	β -lactamase content	MEM MIC ($\mu\text{g/mL}$)	MIC with meropenem fixed at 4 $\mu\text{g/mL}$ ($\mu\text{g/mL}$)						
				20	17	1	3	VAB	TZB	AVI
<i>K. pneumoniae</i>	ATCC BAA 1705	KPC-2	16	0.015	0.015	0.0079	0.0079	0.03	8	0.015
<i>K. pneumoniae</i>	CDC-0040	VIM-27, CTX-M-15, SHV-11, OXA-1	>128	8	>16	>16	>16	>16	>16	>16
<i>E. coli</i>	CDC-0055	NDM-1, CMY-6, OXA-1	32	0.25	8	16	1	>16	>16	8
<i>K. pneumoniae</i>	CDC-0066	OXA-232, OXA-9, TEM-1A, CTX-M-15, OXA-1	32	4	8	2	4	>16	>16	2
<i>P. aeruginosa</i>	CDC-0356	KPC-2, PDC-42	32	1	4	2	1	8	>16	0.5
<i>K. pneumoniae</i>	CDC-0361	KPC-2, SHV-12, TEM-1	16	0.015	0.015	0.0079	0.0079	0.06	>16	0.015
<i>E. coli</i>	CDC-0452	NDM	32	0.25	8	8	2	>16	>16	8
<i>P. aeruginosa</i>	CDC-0457	VIM	128	>16	>16	>16	>16	>16	>16	>16

binding mode of **20**/CTX-M-15 is very similar to that observed by Cahill et al. in the cocrystal structure of a different cyclic boronate with CTX-M-15 (PDB code 5T66).²⁰ In addition, for class C SBL (AmpC) and class D SBL (OXA-10), crystallography studies also revealed that the cyclic boronate mimics the tetrahedral oxyanion with an overall similar conformation.^{19,22,33}

The structure of **20**/VIM-2 (Figure 4B) revealed that the tetrahedral boron of **20** was bound to the active-site zinc atom (Zn1), thus mimicking the tetrahedral intermediate formed following the nucleophilic attack of the BL carbonyl by the hydroxide anion. The second active-site zinc atom (Zn2) was extensively coordinated by the carboxylate and phenolic oxygen atoms. In contrast with the class A enzyme, in which the amido group substituent does not interact with any of the enzyme residues, the proximal amine of **20** interacted with Glu149 in the **20**/VIM-2 structure. This additional hydrogen-bonding interaction between the side chain and the enzyme in

the **20**/VIM-2 structure is also noticed in the binding mode of another cyclic boronate in complex with VIM-2 reported by Brem et al. (PDB code 5FQC).¹⁹ Interestingly, a cocrystal structure of **20** complexed within NDM-1 showed that in addition to the anticipated bicyclic form, a tricyclic structure that resulted from the cyclization of the amide oxygen onto the boron atom was also observed (PDB code 6RMF).²² This observation suggests that boronate-based BLIs are able to adapt multiple forms when interacting with different enzymes. The same study revealed that despite a variety of differing side-chain orientations, the binding mode of the fused bicyclic boronate motif was strikingly conserved in both SBLs and MBLs.²² Taken together, the scaffold with a cyclic boronate fused to a benzoic acid is demonstrated to be the key binding motif for pan- β -lactamase inhibition.

On the basis of these structural studies, we conclude that **20** and its analogues act as pan-BLIs by mimicking the common tetrahedral intermediates proposed for substrate hydrolysis by

Table 8. Rescue of Cefepime Activity by BLI in Serine- β -lactamase-Expressing Enterobacteriaceae

strain	β -lactamase content ^a	MIC ($\mu\text{g}/\text{mL}$) ^b		
		cefepime	cefepime/TZB	cefepime/20
<i>E. coli</i> EC1552	ESBL/C	16	4	0.5
<i>E. coli</i> CH1	ESBL/C	>128	16	<0.125
<i>E. cloacae</i> CH23	ESBL/C	>128	>16	0.5
<i>K. pneumoniae</i> 9032	ESBL	64	4	<0.125
<i>K. pneumoniae</i> 664-1	KPC/C	>128	>16	0.25
<i>K. pneumoniae</i> 964-2	ESBL/KPC	>128	>16	<0.125
<i>K. oxytoca</i> 971	ESBL/D	>128	>16	0.5

^aESBL includes TEM, CTX-M, and SHV types. ^bMIC of cefepime alone or cefepime plus BLI fixed at 4 $\mu\text{g}/\text{mL}$.

both SBL and MBL enzymes and that the *N*-(2-aminoethyl) cyclohexylamine moiety creates further stabilizing interactions within the active site of MBL by targeting conserved and negatively charged residues (such as Glu149 in VIM-2 and NDM-1).

Compound 20 Potentiated β -Lactam-Mediated Antibiotic Activity. The ability of **20** to rescue the activity of the three major subclasses of BLs—piperacillin (PIP) (a ureidopenicillin), cefepime (a fourth-generation oxyimino-cephalosporin), or meropenem (a 1- β -methyl-carbapenem)—when provided at the prescribed fixed concentration was evaluated using MDR β -lactamase-producing Gram-negative clinical isolates (Tables 5–7). For comparison, we also included the known BLs VAB, TZB, and AVI as well as cyclic boronates **1** and **3** and the truncated *trans*-cyclohexylamine analogue (**17**). Compared with **1** and **3**, **20** demonstrated superior potentiation of the antibacterial activity of all three tested BL antibiotics. Specifically, significant improvements were observed in terms of rescuing BL activity on bacterial strains producing class D or class B β -lactamases. In addition, the critical role of the appended aminoethyl group was revealed by a comparison of **20** with truncated **17**, which exhibited inferior performance against many of the tested strains. Finally, the combination of a BL with **20** demonstrated excellent antibacterial activity in BL-resistant strains, which appeared greater than that of the VAB- or TZB-containing BL combinations and better or comparable to that of the AVI/BL combinations. The strong correlation observed between the *in vitro* inhibitory activity on purified β -lactamases and the potentiation effect in whole-cell assays of **20** appeared particularly encouraging. Although **20** rescued the activity of all relevant anti-Gram-negative BLs including meropenem (*vide supra*), we selected the fourth-generation cephalosporin cefepime as the preferred development partner for **20**. This selection was driven by the following considerations: (i) Cefepime is considered the most advanced “broad-spectrum” cephalosporin, with demonstrated safety and efficacy for infections caused by major Gram-positive organisms including *Staphylococcus aureus* and *Streptococcus pneumoniae* as well as important Gram-negative pathogens, including *B. mallei* and *B. pseudomallei*, *Salmonella* spp., *E. coli*, *K. pneumoniae*, *Enterobacter* spp., and *P. aeruginosa*. (ii) Pharmacokinetic (PK) analysis suggested that cefepime and **20** would be compatible. (iii) Cefepime plus **20** would avoid the resistance-selective pressure derived by the further usage of carbapenems, as would be the case for meropenem plus **20**.

Compound 20 Reduced Cefepime MIC in Serine- β -lactamase-Expressing Enterobacteriaceae. To evaluate the activity of cefepime plus **20** against SBL-producing Enterobacteriaceae, cefepime MICs were determined alone

or with a fixed concentration of **20** or TZB (4 $\mu\text{g}/\text{mL}$) against a panel of Gram-negative isolates producing class A ESBLs or KPCs, class C cephalosporinases, or class D oxacillinases. As described in Table 8, these cefepime-resistant strains were susceptible to cefepime/20 at MIC ranges below the Clinical and Laboratory Standards Institute’s (CLSI) susceptible-dose dependent (SDD) breakpoint of 8 $\mu\text{g}/\text{mL}$. By comparison, cefepime/TZB demonstrated only modest activity in three of the eight strains, which is likely due to the presence of class C or KPC-type β -lactamases.

Compound 20 Rescued Cefepime Activity against Metallo- β -lactamase-Producing Gram-Negative Pathogens. Fourteen clinical isolates expressing Ambler class B VIM- or NDM-type MBLs were tested for susceptibility to cefepime alone or cefepime in combination with **20**, TZB, or AVI. The test set included 10 cefepime-resistant strains of Enterobacteriaceae, one strain of *P. aeruginosa*, and three strains of *A. baumannii*. Not surprisingly, on the basis of their lack of enzyme inhibition, neither TZB nor AVI had any effect on the susceptibility of these organisms to cefepime (Table 9).

Table 9. Rescue of Cefepime Activity by BLI (Fixed at 4 $\mu\text{g}/\text{mL}$) in 14 Gram-Negative Pathogens Expressing Class B Enzymes^a

entry	MIC range ($\mu\text{g}/\text{mL}$) ^b	MIC ₅₀ ($\mu\text{g}/\text{mL}$)	MIC ₉₀ ($\mu\text{g}/\text{mL}$)	% of strains with MICs ≤ 8 ^c
cefepime	32 to >512	>512	>512	0
cefepime/20	0.125–4	1	4	100
cefepime/TZB	16 to >32	>32	>32	0
cefepime/AVI	16 to >32	>32	>32	0

^aStrains expressed VIM-1 (6), VIM-2 (4), VIM-4 (3), or NDM-1 (1). Strains tested included *E. coli* (4), *E. cloacae* (2), *K. pneumoniae* (4), *P. aeruginosa* (1), and *A. baumannii* (3). ^bMIC testing conducted using CLSI broth microdilution assay with BLI fixed at 4 $\mu\text{g}/\text{mL}$ and cefepime titrated. ^cCLSI SDD breakpoint, M100, 2019.

In contrast, cefepime plus **20** displayed potent antibacterial activity on these difficult-to-treat organisms. Notably, the addition of **20** elicited a ≥ 512 -fold decrease in the MIC of cefepime in these resistant organisms. In these 14 MBL-producing strains, cefepime plus **20** resulted in MIC₅₀/MIC₉₀ values of 1 and 4 $\mu\text{g}/\text{mL}$, respectively.

Compound 20 Displayed No Intrinsic Antibacterial Activity. DBO BLIs are reported to possess stand-alone antibacterial activity owing to the inhibition of penicillin-binding protein 2 (PBP2), which can lead to rapid resistance development.^{34,35} To ascertain whether **20** possessed any intrinsic antibacterial activity, meropenem, oxacillin, and **20** were independently tested against a panel of both Gram-

Table 10. Antibacterial Activity of **20**, Meropenem, and Oxacillin

species	strain ID	β -lactamase content	MIC ($\mu\text{g}/\text{mL}$)		
			20	meropenem	oxacillin
<i>S. aureus</i>	29213	W/T	>128	0.06	0.125
<i>S. aureus</i>	33591	MRSA	>128	32	>128
<i>E. coli</i>	25922	W/T	>128	0.03	>128
<i>E. coli</i>	J53	SHV5, AmpC, TEM-1	>128	0.06	>128
<i>K. pneumoniae</i>	CI 09	W/T	>128	0.06	>128
<i>K. pneumoniae</i>	UMM	SHV5, KPC-2, TEM-1	>128	16	>128
<i>K. pneumoniae</i>	A-1797	KPC-2, VIM-4, CMY-4	>128	128	>128
<i>K. pneumoniae</i>	11978	OXA-48	>128	64	>128
<i>E. cloacae</i>	144200	p99 AmpC	>128	0.25	>128
<i>E. aerogenes</i>	188548	AmpC	>128	2	>128
<i>P. aeruginosa</i>	27853	W/T	>128	1	>128
<i>P. aeruginosa</i>	Ps296	AmpC, VIM-2, TEM-1	>128	64	>128

positive and Gram-negative bacteria. Unlike meropenem and oxacillin, **20** was devoid of intrinsic antibacterial activity and thus was acting solely as a BLI (Table 10).

Compound 20 Selectively Inhibited β -Lactamase Enzymes. BLI **20** displayed no cytotoxicity when tested up to 256 $\mu\text{g}/\text{mL}$ (i.e., <20% inhibition of growth observed) against three mammalian cell lines (i.e., HeLa, MRC-5, and 3T3). Because compounds possessing low clogP and high aqueous solubility are typically excreted via the kidney, we included an assessment of toxicity in human primary renal proximal tubule cells. No toxicity was observed in human primary proximal tubule cells when **20** was tested up to 1000 $\mu\text{g}/\text{mL}$.

Compound **20** had no significant activity when tested against a panel of 50 human enzymes and receptors at a concentration of 100 μM . The panel included serine proteases (i.e., cathepsin G, chymotrypsin, Factor Xa, trypsin, and neutrophil elastase 2), metalloproteinases (MMP-1, -2, -3, and -9), cytochrome P450s (1A2, 2C9, 2C19, 2D6, and 3A4), and the hERG potassium channel.

Combination of Cefepime Plus 20 Displayed Antibacterial Efficacy in Vivo. Compound **20** demonstrated a PK profile in mice that is typical of highly polar, ionizable compounds and is similar to the PK profile of known β -lactams (i.e., V_{ss} consistent with good diffusion to tissue and low-to-moderate plasma clearance; Table 11). In comparison with AVI, **20** exhibited higher exposure (AUC) and lower clearance.

Table 11. Pharmacokinetic Parameters of **20**, Cefepime, and AVI in Mice Following Intravenous Administration

entry	$t_{1/2}$ (h)	AUC _{inf} (h-ng/mL)	V_{ss} (mL/kg)	CL (mL/h/kg)
20	0.16	16 189	143	618
cefepime	0.39	15 800	330	648
AVI	0.1	8075	210	1238

The in vivo efficacy of cefepime/**20** was assessed in both the neutropenic mouse lung infection model against a CTX-M-14-producing strain of *K. pneumoniae* and in the ascending urinary tract infection model against a CTX-M-15-producing strain of *E. coli* (Figure 5). In the former, cefepime alone, when dosed subcutaneously at 32 mg/kg, was not effective at reducing viable bacterial counts in lung tissue. A single subcutaneous dose of cefepime/**20** (32 and 16 mg/kg, respectively), however, achieved >4 log₁₀ reduction in viable bacterial counts. In the latter model, twice-a-day cefepime/**20** (16 and 8

mg/kg, respectively) demonstrated >2 log₁₀ reductions in viable bacterial counts in the kidney.

Boronate **20** also demonstrated a clean safety profile in the preclinical toxicity evaluation. A phase-1 clinical trial of **20** including SAD, MAD, and DDI studies has been completed.³⁶ A phase 3 efficacy trial of cefepime plus **20** is in progress (under registration no. NCT03840148 at ClinicalTrials.gov).

CONCLUSIONS

Starting from a cyclic boronate template, we have discovered a highly potent inhibitor of all four Ambler classes of β -lactamase enzymes that is also correspondingly highly active in a wide range of Gram-negative bacteria. The *N*-(2-aminoethyl)-cyclohexylamine side chain of **20** (VNRX-5133) proved to be critical for broad-spectrum β -lactamase inhibition and enhanced Gram-negative outer membrane permeability and periplasmic accumulation. Structural studies revealed that the pan- β -lactamase inhibition is due to **20** mimicking the tetrahedral intermediates of both the serine-based and zinc-based enzymatic hydrolysis processes. The synthetic chemistry to **20** relied on two successive Matteson homologations, the latter of which installed an α -chloroboronate with high stereoselectivity.

Boronate **20** is selective for bacterial enzymes and is nontoxic to mammalian cells. Boronate **20** demonstrated the potent in vivo rescue of cefepime activity in both the murine neutropenic lung infection model and the murine ascending urinary tract infection model. Compound **20** is the first pan-spectrum BLI to enter clinical development.

EXPERIMENTAL SECTION

General Methods. All solvents and reagents were purchased from commercial vendors and were used without further purification unless otherwise mentioned. Column chromatography was conducted using prepacked silica gel cartridges (Biotage) on a Biotage Isolera Prime system. LC-MS was conducted on an Agilent 1100 series HPLC apparatus and a 6120 Quadrupole LC-MS apparatus in API-ES mode using a Waters Xbridge C18 column (4.6 mm \times 50 mm, 3.5 μm). Mobile phase A was 0.1% trifluoroacetic acid in water, and mobile phase B was 0.1% trifluoroacetic acid in acetonitrile. ¹H NMR spectra were obtained using a Varian Mercury 300 MHz spectrometer. The final products were purified by preparative HPLC on a Waters XBridge C18 column (19 mm \times 100 mm, 3.5 μm). The purity of all tested compounds was $\geq 95\%$, as determined by HPLC with UV detection at 220 nm and ¹H NMR analyses.




Figure 5. Results of cefepime/VNRX-5133 in the neutropenic mouse lung infection model and ascending urinary tract infection model. (A) Neutropenic mouse lung infection model experiment. The MICs for cefepime alone and cefepime/VNRX-5133 against *K. pneumoniae* were 64 and ≤ 0.125 $\mu\text{g/mL}$, respectively. At 24 h, \log_{10} CFU/lung values for cefepime alone, cefepime/VNRX-5133 (32:16), and positive control Caz/Avi (32:8) were 9.27 ± 0.21 , 4.51 ± 0.12 , and 5.13 ± 0.54 , respectively. (B) Mouse ascending urinary tract infection model. The MICs for cefepime alone and cefepime/VNRX-5133 against *E. coli* were 128 and 0.5 $\mu\text{g/mL}$, respectively. At day 7, \log_{10} CFU/kidney values for cefepime alone, cefepime/VNRX-5133 (16:8), and positive control Caz/Avi (16:4) were 7.25 ± 0.16 , 4.87 ± 0.43 , and 5.58 ± 0.67 , respectively.

All animal experiments performed in the manuscript were conducted in compliance with institutional guidelines, as defined by the Institutional Animal Care and Use Committee (IACUC).

2-Methoxy-3-(2,9,9-trimethyl-3,5-dioxa-4-bora-tricyclo[6.1.1.0_{2,6}]-dec-4-ylmethyl)-benzoic Acid *tert*-Butyl Ester (5). A solution of 2-methoxy-3-(2,9,9-trimethyl-3,5-dioxa-4-bora-tricyclo[6.1.1.0_{2,6}]-dec-4-yl)-benzoic acid *tert*-butyl ester (9.78 g, 25.3 mmol) and chloriodomethane (2.9 mL, 39.8 mmol) in THF (72 mL) under argon was cooled to -100 °C (MeOH/liquid N₂ bath). *n*-BuLi (15.0 mL, 2.5 M in hexanes, 37.5 mmol) was added dropwise over 25 min. The reaction was allowed to slowly warm to room temperature and was stirred for a total of 17.5 h. The reaction mixture was quenched with water and extracted three times with EtOAc. The combined organic layer was washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. Purification by flash silica gel chromatography (0–7% EtOAc/hexane) provided 8.92 g (88%) of 5 as a clear oil. ESI-MS *m/z*: 401.1 (M + H)⁺.

***tert*-Butyl 3-((S)-2-Chloro-2-((3a*S*,4*S*,6*S*,7a*R*))-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)ethyl)-2-methoxybenzoate (6).** To a solution of DCM (19.4 mL, 303 mmol) in THF (276 mL) at -100 °C (MeOH/liquid N₂ bath) was added dropwise *n*-BuLi (77.4 mL, 193 mmol, 2.5 M in hexanes) over a period of 40 min. After the addition was completed, the resulting white milky mixture was stirred for 30 min; then, a solution of 2-methoxy-3-(2,9,9-trimethyl-3,5-dioxa-4-bora-tricyclo[6.1.1.0_{2,6}]-dec-4-ylmethyl)-benzoic acid *tert*-butyl ester 5 (55.3 g, 138 mmol) in THF (100 mL) was added dropwise over 30 min. After the addition was completed, the mixture was stirred for 45 min; then, a solution of ZnCl₂ (182 mL, 182 mmol, 1.0 M in ether) was added slowly over 30 min, and stirring continued for an additional 5 min. The reaction mixture was stirred for 80 min at -10 °C (dry ice in acetone). The resulting yellow solution was diluted with ether (1000 mL) and washed with HCl (0.05M, 800 mL). The organic layer was separated, washed with brine, dried over anhydrous Na₂SO₄, concentrated, and chromatographed on a silica gel (500 g) column eluted with hexanes/EtOAc (2–5%) to give 6 as a colorless oil (56.5 g, 91.2% yield), which was used directly in the next step. ESI-MS *m/z*: 471.2 (M + Na)⁺.

General Method for the Preparation of Compound 8. To a solution of *tert*-butyl 3-((S)-2-chloro-2-((3a*S*,4*S*,6*S*,7a*R*))-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)ethyl)-2-methoxybenzoate 6 (1.35g, 3 mmol) in THF (9 mL) at -20 °C was added dropwise a solution of lithium bistrimethylsilylamide (3.0 mL, 1 M in THF, 3 mmol). Following the addition, the bath was removed, and stirring continued for 17 h. The resulting solution, containing ~ 0.25 M of intermediate 7 in THF, was used without further purification.

To a mixture of carboxylic acid (1 mmol) and HATU (418 mg, 1.1 mmol) was added DMA (3 mL), followed by *N*-methyl-morpholine (120 μL , 1.1 mmol). The resulting solution was stirred for 90 min. To this solution was added a solution of 7 (4 mL, ~ 0.25 M in THF, 1 mmol). The resulting mixture was stirred for 2.5 h, diluted with EtOAc, washed with water and brine, dried over anhydrous Na₂SO₄, filtered, and concentrated. The residue was purified by silica gel chromatography (10 g silica; eluted with 20–100% EtOAc/hexanes) to provide amide 8.

General Method for the Preparation of Compound 9. To a solution of amide 8 (0.30 mmol) in anhydrous DCM (5 mL) at -78 °C was added BCl₃ (2.1 mL, 1 M in DCM, 2.1 mmol). After 1 h, the reaction mixture was warmed to 0 °C. After 1 h, the reaction mixture was quenched by the addition of water (5 mL) at 0 °C. The aqueous phase was washed with DCM and then purified by reverse-phase preparative HPLC. The product-containing fractions were combined and lyophilized to dryness.

2-(*trans*-4-((*tert*-Butoxycarbonyl)(2-((*tert*-butoxycarbonyl)amino)ethyl)amino)cyclohexyl)Acetic Acid (14). To a solution of Boc-*trans*-4-aminocyclohexane acetic acid (10, 5.14 g, 20 mmol) in DMF (60 mL) was added K₂CO₃ (3.32 g, 24 mmol), followed by benzyl bromide (2.62 mL, 22 mmol). The reaction mixture was stirred at ambient temperature overnight, quenched by the addition of water (250 mL), and extracted with diethyl ether (2 \times 200 mL). The organic extracts were combined, washed successively with water, saturated aqueous NaHCO₃, and brine, dried over anhydrous Na₂SO₄, and concentrated in vacuo to yield 11 (6.94 g, quant. yield) which was used without further purification.

Compound **11** was dissolved in DCM (20 mL), treated with 4 M HCl in dioxane (100 mL, 400 mmol) at ambient temperature for 1 h, then concentrated in vacuo to give amine **12**, which was used for the next step without further purification.

To a solution of **12** (3.78 g, 13.4 mmol) in DCE (220 mL) was added triethylamine (1.9 mL, 13.6 mmol), followed by HOAc (0.8 mL, 13.4 mmol), *N*-Boc-2-aminoacetaldehyde (3.05 g, 19.32 mmol), and NaBH(OAc)₃ (4.15 g, 19.6 mmol). The reaction mixture was stirred at ambient temperature for 3 h then quenched with saturated aqueous NaHCO₃. The organic layer was separated, and the aqueous phase was extracted with DCM. The combined organic extracts were dried over anhydrous Na₂SO₄ then concentrated in vacuo to provide crude **13**.

Crude **13** was dissolved in DCM (200 mL) containing triethylamine (2.8 mL, 20 mmol) and Boc₂O (3.5 g, 16 mmol). The reaction mixture was stirred at ambient temperature overnight, concentrated to dryness, then purified by flash silica gel column chromatography (hexane/EtOAc 40:1–2:1) to afford the crude benzyl ester (3.3 g, 62% yield over three steps), which was dissolved in EtOAc (250 mL) and hydrogenated in the presence of 10% Pd/C (700 mg) at ambient temperature overnight. The reaction mixture was filtered through a pad of celite. The filtrate was concentrated and purified by flash silica gel column chromatography (hexane/acetone 10:1 to 1:1) to afford the acid **14** (2.35 g, 44% yield). ¹H NMR (CD₃OD) δ 3.8–3.6 (m, 1H), 3.15 (br s, 4H), 2.17 (d, 2H, *J* = 7.2 Hz), 1.92–1.80 (m, 2H), 1.78–1.50 (m, 5H), 1.46 (s, 9H), 1.43 (s, 9H), 1.14–1.07 (m, 2H). ESI-MS *m/z*: 423.3 (M + Na)⁺.

(3R)-3-(2-{trans-4-[(2-Aminoethyl)amino]cyclohexyl}acetamido)-2-hydroxy-3,4-dihydro-2H-1,2-benzoxaborin-8-carboxylic Acid (20/VNRX-5133). Compound **20** was synthesized following the general procedure for the synthesis of **8** and **9**. ¹H NMR (D₂O) δ 7.84 (d, 1H, *J* = 6.9 Hz), 7.49 (d, 1H, *J* = 6.9 Hz), 7.13 (t, 1H, *J* = 7.5 Hz), 3.41–3.38 (m, 4H), 3.32 (s, 1H), 3.02–2.99 (m, 2H), 2.85–2.81 (m, 1H), 2.38–2.35 (m, 1H), 2.18–2.13 (m, 1H), 1.93–1.90 (m, 1H), 1.88–1.85 (m, 1H), 1.47–1.44 (m, 1H), 1.41–1.37 (m, 1H), 1.24–1.20 (m, 1H), 1.10–1.05 (m, 1H), 0.88–0.84 (m, 1H), 0.71–0.67 (m, 1H), 0.54–0.50 (m, 1H). ESI-MS *m/z*: 390.2 (M + H)⁺. The final enantiomeric purity was measured by chiral HPLC to be >98% (column: Daicel Crownpak CR (-), 150 mm × 4.0 mm, 5 μm; mobile phase: 1% (v/v) HClO₄ in H₂O).

X-ray Crystallography. The CTX-M-15 and VIM-2 β-lactamases were purified and crystallized using the sitting drop method, as previously described.^{37–39} Crystals of the native enzymes were soaked for up to 60 min with a 5 mM inhibitor (**20**) solution in the crystallization buffer prior to flash-freezing in the presence of ethylene glycol as the cryoprotectant. X-ray diffraction data were collected at the European Radiation Synchrotron Facility (ESRF, Grenoble, France) or the Diamond Light Source (Didcot, UK). Data were processed as described elsewhere,^{40,41} and the structures obtained by molecular replacement using the native structure of the corresponding enzymes (CTX-M-15, PDB code 4HBT; VIM-2, PDB code 1KO3), excluding solvent and other ligands. Refinement was performed with REFMAC5⁴² from the CCP4 suite using an iterative manual rebuilding and modeling of missing atoms in the electron density using COOT.⁴³ Water molecules were added using the standard procedures implemented in the ARP/wARP suite.⁴⁴ Data collection and model refinement statistics are shown in Table S1.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01518>.

Inhibition assays, antimicrobial susceptibility testing, pharmacokinetic studies in mice, mouse efficacy studies, and X-ray data collection and model refinement statistics (Table S1) (PDF)

Molecular formula strings (XLSX)

Accession Codes

PDB codes 6SP6 (CTX-M-15/20) and 6SP7 (VIM-2/20).

■ AUTHOR INFORMATION

Corresponding Authors

*E-mail: burns@venatorx.com (C.J.B.).

*E-mail: liu@venatorx.com (B.L.).

ORCID

Bin Liu: 0000-0002-2538-312X

Cecilia Pozzi: 0000-0003-2574-3911

Filomena De Luca: 0000-0002-7170-1555

Manuela Benvenuti: 0000-0003-0709-2537

Stefano Mangani: 0000-0003-4824-7478

Jean-Denis Docquier: 0000-0001-9483-4476

Notes

The authors declare the following competing financial interest(s): B.L., R.T., G.C., D.M., R.J., J.H., D.D., S.C., D.P., L.X., and C.B. are employees of Venatorx Pharmaceuticals.

■ ACKNOWLEDGMENTS

This project has been funded in whole or in part from the National Institute for Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract no. HHSN272201300019C and the Wellcome Trust under award no. 360G-Wellcome-101999/Z/13/Z. We thank Cassandra Chatwin and Kaitlyn John for generating MIC data. We thank Dr. Stephen M. Condon for helpful discussions and the review of this manuscript.

■ ABBREVIATIONS USED

BLI, β-lactamase inhibitor; BL, β-lactam antibiotic; PBP, penicillin-binding protein; MDR, multi-drug-resistant; SBL, serine β-lactamase; MBL, metallo-β-lactamase; NDM, New Delhi metallo-β-lactamase; IMP, imipenemase; VIM, Verona integron metallo β-lactamase; KPC, *Klebsiella pneumoniae* carbapenemase; ESBL, extended spectrum β-lactamase; MIC, minimum inhibitory concentration; SAR, structure–activity relationship; TZB, tazobactam; AVI, avibactam; AUC, area under the curve; CL, clearance; V_{ss}, steady-state volume of distribution; PK, pharmacokinetic; SAD, single ascending dose; MAD, multiple ascending dose; DDI, drug–drug interaction; OM, outer membrane

■ REFERENCES

- (1) Elander, R. P. Industrial production of beta-lactam antibiotics. *Appl. Microbiol. Biotechnol.* **2003**, *61*, 385–392.
- (2) Queenan, A. M.; Bush, K. Carbapenemases: the versatile beta-lactamases. *Clin. Microbiol. Rev.* **2007**, *20*, 440.
- (3) Bush, K.; Jacoby, J. A. Updated functional classification of β-lactamases. *Antimicrob. Agents Chemother.* **2010**, *54*, 969.
- (4) Palzkill, T. Metallo-β-lactamase structure and function. *Ann. N. Y. Acad. Sci.* **2013**, *1277*, 91–104.
- (5) Watkins, R. R.; Bonomo, R. A. Increasing prevalence of carbapenem-resistant Enterobacteriaceae and strategies to avert a looming crisis. *Expert Rev. Anti-Infect. Ther.* **2013**, *11*, 543–545.
- (6) Papp-Wallace, K. M.; Bonomo, R. A. New β-lactamase inhibitors in the clinic. *Infect. Dis. Clin. North Am.* **2016**, *30*, 441–464.
- (7) Ehmman, D. E.; Jahić, H.; Ross, P. L.; Gu, R. F.; Hu, J.; Kern, G.; Walkup, G. K.; Fisher, S. L. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. *Proc. Natl. Acad. Sci. U. S. A.* **2012**, *109*, 11663–11668.
- (8) Hecker, S. J.; Reddy, K. R.; Totrov, M.; Hirst, G. C.; Lomovskaya, O.; Griffith, D. C.; King, P.; Tsvikovski, R.; Sun, D.;

- Sabet, M.; Tarazi, Z.; Clifton, M. C.; Atkins, K.; Raymond, A.; Potts, K. T.; Abendroth, J.; Boyer, S. H.; Loutit, J. S.; Morgan, E. E.; Durso, S.; Dudley, M. N. Discovery of a cyclic boronic acid β -lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. *J. Med. Chem.* **2015**, *58*, 3682–3692.
- (9) Smoum, R.; Rubinstein, A.; Dembitsky, V. M.; Srebnik, M. Boron containing compounds as protease inhibitors. *Chem. Rev.* **2012**, *112*, 4156–4220.
- (10) Kiener, P. A.; Waley, S. G. Reversible inhibitors of penicillinases. *Biochem. J.* **1978**, *169*, 197–204.
- (11) Beesley, T.; Gascoyne, N.; Knott-Hunziker, V.; Petursson, S.; Waley, S. G.; Jaurin, B.; Grundstrom, T. The inhibition of class C β -lactamases by boronic acids. *Biochem. J.* **1983**, *209*, 229–233.
- (12) Strynadka, N. C.; Adachi, H.; Jensen, S. E.; Johns, K.; Sielecki, A.; Betzel, C.; Sutoh, K.; James, M. N. Molecular structure of the acylenzyme intermediate in beta-lactam hydrolysis at 1.7 Å resolution. *Nature* **1992**, *359*, 700–705.
- (13) Strynadka, N. C.; Martin, R.; Jensen, S. E.; Gold, M.; Jones, J. B. Structure-based design of a potent transition state analogue for TEM-1 beta-lactamase. *Nat. Struct. Mol. Biol.* **1996**, *3*, 688–695.
- (14) Wang, X.; Minasov, G.; Blazquez, J.; Caselli, E.; Prati, F.; Shoichet, B. K. Recognition and resistance in TEM beta-lactamase. *Biochemistry* **2003**, *42*, 8434–8444.
- (15) Morandi, F.; Caselli, E.; Morandi, S.; Focia, P. J.; Blazquez, J.; Shoichet, B. K.; Prati, F. Nanomolar inhibitors of AmpC beta-lactamase. *J. Am. Chem. Soc.* **2003**, *125*, 685–695.
- (16) Burns, C. J.; Goswami, R.; Jackson, R. W.; Lessen, T.; Li, W.; Pevear, D.; Tirunahari, P. K.; Xu, H. Beta-Lactamase Inhibitors. WO 2010130708 A1, 2010.
- (17) Burns, C. J.; Daigle, D.; Liu, B.; McGarry, D.; Pevear, D. C.; Trout, R. E. L. Beta-Lactamase Inhibitors. WO 2014089365 A1, 2014.
- (18) Burns, C. J.; Daigle, D.; Liu, B.; Jackson, R. W.; Hamrick, J.; McGarry, D.; Pevear, D. C.; Trout, R. E. L. Beta-Lactamase Inhibitors. WO 2015191907 A1, 2015.
- (19) Brem, J.; Cain, R.; Cahill, S.; McDonough, M. A.; Clifton, I. J.; Jiménez-Castellanos, J. C.; Avison, M. B.; Spencer, J.; Fishwick, C. W.; Schofield, C. J. Structural basis of metallo- β -lactamase, serine- β -lactamase and penicillin-binding protein inhibition by cyclic boronates. *Nat. Commun.* **2016**, *7*, 12406–12415.
- (20) Cahill, S. T.; Cain, R.; Wang, D. Y.; Lohans, C. T.; Wareham, D. W.; Oswin, H. P.; Mohammed, J.; Spencer, J.; Fishwick, C. W. G.; McDonough, M. A.; Schofield, C. J.; Brem, J. Cyclic boronates inhibit all classes of β -Lactamases. *Antimicrob. Agents Chemother.* **2017**, *61*, No. e02260-e02216.
- (21) Krajnc, A.; Lang, P. A.; Panduwawala, T. D.; Brem, J.; Schofield, C. J. Will morphing boron-based inhibitors beat the beta-lactamases? *Curr. Opin. Chem. Biol.* **2019**, *50*, 101–110.
- (22) Krajnc, A.; Brem, J.; Hinchliffe, K.; Calvopiña, K.; Panduwawala, T. D.; Lang, P. A.; Kamps, J. J. A. G.; Tyrrell, J. M.; Widlake, E.; Saward, B. G.; Walsh, T. R.; Spencer, J.; Schofield, C. J. Bicyclic boronate VNRX-5133 inhibits metallo- and serine- β -lactamases. *J. Med. Chem.* **2019**, *62*, 8544–8556.
- (23) Burns, C. J.; Liu, B.; Chu, G.; Trout, R.; Jackson, R.; McGarry, D.; Hamrick, J.; Daigle, D.; Cusick, S.; Pevear, D.; Xerri, L. Discovery of VNRX-5133: A Broad-Spectrum Serine- and Metallo- β -lactamase Inhibitor (BLI) for Carbapenem-Resistant Bacterial Infections (“Superbugs”). Proceedings of the 255th National Meeting of the American Chemical Society, New Orleans, LA, 2018; American Chemical Society: Washington, DC, 2018; Abstract MEDI-309.
- (24) Ness, S.; Martin, R.; Kindler, A. M.; Paetzel, M.; Gold, M.; Jensen, S. E.; Jones, J. B.; Strynadka, N. C. Structure-based design guides the improved efficacy of deacylation transition state analogue inhibitors of TEM-1 beta-lactamase. *Biochemistry* **2000**, *39*, 5312–5321.
- (25) Linciano, P.; Cendron, L.; Gianquinto, E.; Spyrikis, F.; Tondi, D. Ten Years with New Delhi Metallo- β -lactamase-1 (NDM-1): From structural insights to inhibitor design. *ACS Infect. Dis.* **2019**, *5*, 9–34.
- (26) Delcour, A. H. Outer membrane permeability and antibiotic resistance. *Biochim. Biophys. Acta, Proteins Proteomics* **2009**, *1794*, 808–816.
- (27) O’Shea, R.; Moser, H. E. Physicochemical properties of antibacterial compounds: implications for drug discovery. *J. Med. Chem.* **2008**, *51*, 2871–2878.
- (28) Matteson, D. S. α -Halo boronic esters in asymmetric synthesis. *Tetrahedron* **1998**, *54*, 10555–10607.
- (29) Gunaydin, H.; Bartberger, M. D. Stacking with no planarity. *ACS Med. Chem. Lett.* **2016**, *7*, 341–344.
- (30) Richter, M. F.; Drown, B. S.; Riley, A. P.; Garcia, A.; Shirai, T.; Svec, R. L.; Hergenrother, P. J. Predictive compound accumulation rules yield a broad-spectrum antibiotic. *Nature* **2017**, *545*, 299–304.
- (31) Tooke, C. L.; Cain, R.; Tyrrell, J. M.; Hinchliffe, P.; Calvopiña, K.; Langley, G. W.; Widlake, E.; Dowson, C. G.; Spencer, J.; Walsh, T. R.; Schofield, C. J.; Brem, J. Profiling interactions of vaborbactam with metallo- β -lactamases. *Bioorg. Med. Chem. Lett.* **2019**, *29*, 1981–1984.
- (32) Docquier, J.-D.; De Luca, F.; Benvenuti, M.; Pozzi, C.; Daigle, D. M.; Pevear, D. C.; Burns, C. J.; Mangani, S. *Structural Basis for Serine- and Metallo- β -lactamase Inhibition by VNRX-5133, a New β -Lactamase Inhibitor (BLI) in Clinical Development*; European Congress of Clinical Microbiology and Infectious Diseases (ECCMID): Madrid, Spain, 2018.
- (33) Cahill, S. T.; Tyrrell, J. M.; Navratilova, I. H.; Calvopiña, K.; Robinson, S. W.; Lohans, C. T.; McDonough, M. A.; Cain, R.; Fishwick, C. W. G.; Avison, M. B.; Walsh, T. R.; Schofield, C. J.; Brem, J. Study on the inhibition of AmpC and other beta-lactamases by cyclic boronates. *Biochim. Biophys. Acta, Gen. Subj.* **2019**, *1863*, 742–748.
- (34) Morinaka, A.; Tsutsumi, Y.; Yamada, M.; Suzuki, K.; Watanabe, T.; Abe, T.; Furuuchi, T.; Inamura, S.; Sakamaki, Y.; Mitsuhashi, N.; Ida, T.; Livermore, D. M. OP0595, a new diazabicyclooctane: mode of action as a serine β -lactamase inhibitor, antibiotic and β -lactam ‘enhancer’. *J. Antimicrob. Chemother.* **2015**, *70*, 2779–2786.
- (35) Livermore, D. M.; Mushtaq, S.; Warner, M.; Vickers, A.; Woodford, N. In vitro activity of cefepime/zidebactam (WCK 5222) against gram-negative bacteria. *J. Antimicrob. Chemother.* **2017**, *72*, 1373–1385.
- (36) Geibel, B.; Dowell, J.; Dickerson, D.; Henkel, T. 1401. A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single and Repeat Doses of VNRX-5133 in Healthy Subjects. *Open Forum Infect. Dis.* **2018**, *5*, S431.
- (37) Lahiri, S. D.; Mangani, S.; Durand-Reville, T.; Benvenuti, M.; De Luca, F.; Sanyal, G.; Docquier, J.-D. Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and *Pseudomonas aeruginosa* AmpC β -lactamases. *Antimicrob. Agents Chemother.* **2013**, *57*, 2496–2505.
- (38) Docquier, J.-D.; Lamotte-Brasseur, J.; Galleni, M.; Amicosante, G.; Frère, J.-M.; Rossolini, G. M. On functional and structural heterogeneity of VIM-type metallo- β -lactamases. *J. Antimicrob. Chemother.* **2003**, *51*, 257–266.
- (39) Garcia-Saez, I.; Docquier, J.-D.; Rossolini, G. M.; Dideberg, O. The three-dimensional structure of VIM-2, a Zn- β -lactamase from *Pseudomonas aeruginosa* in its reduced and oxidised form. *J. Mol. Biol.* **2008**, *375*, 604–611.
- (40) Docquier, J.-D.; Benvenuti, M.; Calderone, V.; Stoczko, M.; Menciaci, N.; Rossolini, G. M.; Mangani, S. High-resolution crystal structure of the subclass B3 metallo- β -lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides. *Antimicrob. Agents Chemother.* **2010**, *54*, 4343–4351.
- (41) Pozzi, C.; Di Pisa, F.; De Luca, F.; Benvenuti, M.; Docquier, J.-D.; Mangani, S. Atomic-resolution structure of a class C β -lactamase and its complex with avibactam. *ChemMedChem* **2018**, *13*, 1437–1446.
- (42) Murshudov, G. N.; Skubák, P.; Lebedev, A. A.; Pannu, N. S.; Steiner, R. A.; Nicholls, R. A.; Winn, M. D.; Long, F.; Vagin, A. A. REFMAC5 for the refinement of macromolecular crystal structures. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **2011**, *67*, 355–367.

(43) Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features and development of Coot. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **2010**, *66*, 486–501.

(44) Langer, G.; Cohen, S. X.; Lamzin, V. S.; Perrakis, A. Automated macromolecular model building for X-ray crystallography using ARP/wARP version 7. *Nat. Protoc.* **2008**, *3*, 1171–1179.